MEDINCELL S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.36 EUR | -0.12% |
|
+12.21% | +127.22% |
| May. 15 | Medincell: share price falls after disappointing clinical study | CF |
| May. 15 | Transcript : MedinCell S.A. - Special Call |
Presenter SpeechUnknown Executive (Executives)I will do this in English, and someone will tran...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.36
EUR
Average target price
19.24
EUR
Spread / Average Target
+17.60%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +127.22% | 516M | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- Transcript : MedinCell S.A. - Special Call
